Home > Treatment Options > Tumor Suppressors > Clinical Trials >

Axitinib (Inlyta™)

Last Updated: 03/28/17

Status: Currently a NF2 Clinical Trial

Index

  1. Basic Information
  2. Important Information
  3. NF2 Clinical Trial
  4. Other Known Uses
  5. Side Effects
  6. Recommendation

1. Basic Information

Other Names Axitinib, Inlyta, 319460-85-0, AG-013736, AG 013736; UNII-C9LVQ0YUXG, AG013736, S1005_Selleck, AG-013736, AG-13736
Trade Name Inlyta™
Pharmaceutical Company Pfizer
Treatment By Pill - Oral
Tumor Target Vestibular Schwannoma
NF2 Trials Recruiting Trial: NCT02129647
Inhibitor TKI Small Molecule - Tyrosine Kinase Inhibitor and Vascular Epidermal Growth Factor Receptor
Molecular Formula C22H18N4OS
IUPAC N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide
ChemSpider 4953153
PubChem CID 6450551

2. Other Known Uses

  • Breast Cancer
  • Renal Cell Carcinoma (RCC)
  • In Research for: Mesothelioma

3. Side Effects

  • High Blood Pressure / Nosebleeds
  • Diarrhea
  • Fatigue / Tiredness
  • Decrease in Appetite
  • Nausea / Vomiting
  • Hoarseness / Dry Thrroat
  • Skin Conditions - Dry Skin and Blisters
  • Constipation

4. Recommendation

  • Drinking extra water or diluted fluids as well as avoiding fatty, fried, spicy, or highly sweet foods can help with many of the potential side effects.
  • Take Axitinib at night instead of the morning to prevent fatigue.